These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38183017)

  • 21. Current treatment options for monogenic periodic fever syndromes - the role of interleukin 1 inhibitors.
    Milota T; Malcová H; Střížová Z; Cebecauerová D; Horváth R
    Cas Lek Cesk; 2022; 161(1):3-10. PubMed ID: 35354288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 23. A patient with tumor necrosis factor receptor-associated periodic syndrome misdiagnosed as Kawasaki disease: A case report and literature review.
    Gao Y; He X; Xu D; Shen Y; Hang S; Chen D; Chen Y
    Heliyon; 2023 Sep; 9(9):e19751. PubMed ID: 37810071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature.
    Campanilho-Marques R; Brogan PA
    Clin Rheumatol; 2014 Nov; 33(11):1681-4. PubMed ID: 24531849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome.
    Shendi HM; Devlin LA; Edgar JD
    J Clin Rheumatol; 2014 Mar; 20(2):103-5. PubMed ID: 24561416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasculitis in a patient with mevalonate kinase deficiency (MKD): a case report.
    Omoyinmi E; Rowczenio D; Sebire N; Brogan PA; Eleftheriou D
    Pediatr Rheumatol Online J; 2021 Nov; 19(1):161. PubMed ID: 34809655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Mevalonate Kinase Deficiency: A Pediatric Perspective.
    Jeyaratnam J; Frenkel J
    Front Immunol; 2020; 11():1150. PubMed ID: 32582214
    [No Abstract]   [Full Text] [Related]  

  • 29. Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency - A case report.
    Blais J; Bonneville-Roussy D; Elfassy HL; Lanthier S
    J Stroke Cerebrovasc Dis; 2022 Dec; 31(12):106780. PubMed ID: 36242899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab in adult-onset Still's disease: the Israeli experience.
    Elkayam O; Jiries N; Dranitzki Z; Kivity S; Lidar M; Levy O; Ablin J; Abu-Shakra M; Savargyl-Maman H; Padova H; Caspi D; Rosner I
    J Rheumatol; 2014 Feb; 41(2):244-7. PubMed ID: 24429168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report.
    Akasbi N; Soyfoo MS
    Eur J Rheumatol; 2015 Mar; 2(1):35-36. PubMed ID: 27708919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.
    Vinit C; Georgin-Lavialle S; Theodoropoulou A; Barbier C; Belot A; Mejbri M; Pillet P; Pachlopnik J; Poignant S; Rebelle C; Woerner A; Koné-Paut I; Hentgen V
    Front Immunol; 2021; 12():744780. PubMed ID: 34858402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab.
    Benucci M; Meacci F; Grossi V; Infantino M; Manfredi M; Bellio E; Bellio V; Li Gobbi F; Bazzichi L; Moscato P; Caputo D; Saviola G; Talotta R; Sarzi-Puttini P; Atzeni F
    Biologics; 2016; 10():53-8. PubMed ID: 27041992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency.
    Galeotti C; Meinzer U; Quartier P; Rossi-Semerano L; Bader-Meunier B; Pillet P; Koné-Paut I
    Rheumatology (Oxford); 2012 Oct; 51(10):1855-9. PubMed ID: 22740624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG).
    Al-Mayouf SM; Almutairi A; Albrawi S; Fathalla BM; Alzyoud R; AlEnazi A; Abu-Shukair M; Alwahadneh A; Alsonbul A; Zlenti M; Khawaja E; Abushhaiwia A; Khawaja K; AlMosawi Z; Madan W; Almuatiri M; Almuatiri N;
    Rheumatol Int; 2020 Jan; 40(1):49-56. PubMed ID: 31741047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periodic fever syndromes.
    Lachmann HJ
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):596-609. PubMed ID: 29773275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cell transcriptomic analysis in two patients with rare systemic autoinflammatory diseases treated with anti-TNF therapy.
    Hua Y; Wu N; Miao J; Shen M
    Front Immunol; 2023; 14():1091336. PubMed ID: 36911721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.